Table 1.
Lead use of PDE inhibitors in Phase I–III clinical trials.
| Disease Name | Intervention | Target | Trial Phase | Trial Number |
|---|---|---|---|---|
| Traumatic brain injury | Sildenafil | PDE5 | - | NCT02990078 |
| Alzheimer’s disease | Cilostazol | PDE3 | 2 | NCT02491268 |
| Roflumilast | PDE4 | - | NCT02835716 | |
| BPN14770 | PDE4D | 1 | NCT02840279 | |
| BPN14770 | PDE4D | 1 | NCT02648672 | |
| Stroke | Cilostazol | PDE3 | 3 | NCT02481323 |
| Cilostazol | PDE3 | 3 | NCT01995370 | |
| Tadalafil | PDE5 | 2 | NCT02801032 | |
| Sildenafil | PDE5 | 1 | NCT02628847 | |
| Amyotrophic lateral sclerosis | Ibudilast (MN-166) | PDE4 | 1/2 | NCT02714036 |
| Multiple sclerosis | Ibudilast (MN-166) | PDE4 | 2 | NCT01982942 |
| Autonomic nervous system failure and supine hypotension | Sildenafil | PDE5 | 1/2 | NCT00223717 |
| Neonatal encephalopathy | Sildenafil | PDE5 | 1 | NCT02812433 |
| Cerebral vasospasm following sub arachnoid hemorrhage | Milrinone | PDE3 | 2 | NCT02712788 |